Here we build upon these important observations and layer on DNA methylation and histone distribution analyses of metastatic prostate cancer, showcasing how epigenetic changes contribute to tumor phenotype and transcriptional changes, mediating loss of expression of key luminal markers/targets such as the AR and PSMA and gain of new drivers such as ASCL1. The gene discussed is FOLH1; the disease is prostate cancer.